Hydrogen sulfide

• Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, is pleased to announce a moderated poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study.
• The poster will be presented at the 49th Annual Regional Anesthesiology and Acute Pain Medicine Meeting by Dr. Joseph Stauffer, Antibe’s Chief Medical Officer, formerly a practicing anesthesiologist:
  Title: “Assessment of the Pharmacokinetics and Safety of Otenaproxesul, a Non-Abusable, Novel Anti-Inflammatory /Analgesic Compound”
  Location: The Hilton San Diego Bayfront, San Diego, California
  “I am honored by ASRA’s invitation to deliver a moderated poster presentation to my anesthesiologist colleagues,” commented Dr. Stauffer.
• “While surgeons have the primary responsibility for prescribing post-operative analgesics, they often rely on the expertise of anesthesiologists in selecting optimal therapies.
• As we head into otenaproxesul’s Phase II trial, this session is an opportunity to present our novel non-opioid’s strong safety and PK data to physicians seeking safer solutions for pain.”
  The poster will be available in the Scientific Publications section of the Company’s website following the presentation.

• Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, is pleased to announce a poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study.
• The poster will be presented at the 40th Annual Meeting of the American Academy of Pain Medicine by Dr. Joseph Stauffer, Antibe’s Chief Medical Officer:
  Title: “Assessment of the Pharmacokinetic and Safety of Otenaproxesul, a Non-Abusable, Novel, Anti-Inflammatory/Analgesic Compound”
  Location: Westin Kierland Resort & Spa, Scottsdale, Arizona
  “I’m delighted to present these results at the country’s premier gathering of pain specialists,” commented Dr. Stauffer.
• “As they will tell you, the need to minimize opioid use and the lack of innovation in oral analgesics have severely constrained their options for treating pain.
• In the context of resurgent scientific and commercial interest in the pain space, the timing couldn’t be better to discuss new solutions, especially a novel anti-inflammatory compound like otenaproxesul.”
  The poster will be available in the Scientific Publications section of the Company’s website following the presentation.

• Hydrogen sulfide is the gas responsible for the rotten-egg odour that you come across near stagnant water and in drains.
• Bilophila wadsworthia is one such species of these bacteria.
• The bacteria that break down sulfur-containing organic matter and produce hydrogen sulfide are fittingly called sulfate-reducing bacteria.
• Sulfate-reducing bacteria are an important part of the normal human gut microbiome, and small amounts of hydrogen sulfide are required in the human gut environment.

• Bilophila wadsworthia was discovered in the 1980s, when it was found in people who had severe appendicitis.
• The researchers found that it grew really well in bile, which is why the genus name is Bilophila (meaning bile loving).
• Since then, research has associated Bilophila wadsworthia with negative effects in the gut.
• It’s not clear how or why expansion of Bilophila wadsworthia can occur in the gut.

Jade Davies receives funding from UKRI via the BBSRC as part of the Norwich Research Park Doctoral Training Partnership (grant no. BB/M011216/1).

• Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant Exercise Incentive Program (“Early Warrant Exercise Program”) for its 6.4 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 (“Exercise Price”) and expiring on July 31, 2024 (the “Warrants”).
• The existing Early Warrant Exercise Program announced on December 29, 2023 is designed to encourage the early exercise of the Warrants during a 30-day early exercise period that commenced on January 16, 2024 and terminates on February 15, 2024 (the “Incentive Period”).
• Under the Early Warrant Exercise Program, the Company is offering a reduction in the Exercise Price from $1.50 to $1.00 to holders of the Warrants who exercise during the Incentive Period.
• Today’s announcement extends the termination date of the Incentive Period to March 31, 2024 (the “Extension”).